{
  "pmcid": "10299320",
  "sha256": "70f28f47a6899c4ebc3a83c4c0e96267423968bdc52f5f927eabf722beecde07",
  "timestamp_utc": "2025-11-09T23:04:53.754405+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.896447761194032,
    "reading_ease": 19.298925373134352,
    "word_count": 268
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Sutureless Aortic Valve Replacement: A Retrospective Analysis"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants included patients with moderate-to-severe aortic valve disease, with a mean age of 69.3 years and a mean logistic EuroSCORE-II of 5.2%."
      },
      "Intervention": {
        "score": 1,
        "evidence": "sutureless aortic valve replacement (SU-AVR) using the Perceval valve"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aims to review our institutional experience with sutureless aortic valve replacement (SU-AVR) using the Perceval valve."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was mortality at various time points, and secondary outcomes included postoperative complications."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "We conducted a retrospective analysis of 200 consecutive patients who underwent SU-AVR at a single center between December 2019 and February 2023."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "In-hospital, 30-day, 6-month, and 1-year mortality rates were 4.5%, 6.5%, 7.5%, and 8.2%, respectively."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events included re-exploration for bleeding in 7% of patients and permanent pacemaker implantation in 4%."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 10,
    "max_score": 25
  }
}